Ecogen Acquires Exclusive U.K. Licensing And Supply Rights
For New Sildenafil Spray
FOR IMMEDIATE RELEASE AUGUST 19, 2016
Youngsville, Louisiana – RedHawk Holdings Corp. (OTC: IDNG) (“RedHawk” or the “Company”) announced today that EcoGen Europe Limited (“EcoGen”), in which the Company currently has a 25% ownership interest, has signed an exclusive agreement to license and supply a new non-patent infringing generic spray formulation of Sildenafil Citrate (“Sildenafil”) in the U.K. EcoGen will market the new spray under the brand name Azulvig. EcoGen expects to begin marketing the Azulvig in about 12 months after receipt of final U.K. regulatory approval.
While waiting on final U.K. approvals, the Company said it will work with the LSU Innovation Center and the LSU Health Sciences Center to develop the most effective marketing strategy for Azulvig.
Sildenafil, developed by Pfizer, Inc. (NYSE: PFE) and sold as Viagra and other trade names, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. By some estimates, the global erectile dysfunction drug market is expected to reach $3.2 billion by 2022 (Grand View Research Inc., 2015). Sildenafil accounts for more than 40% of the total global market and is generally considered as the first line of treatment for erectile dysfunction (IMS data).
The taste of Azulvig is masked to allow for oral absorption through sub-lingual or buccal membranes. The oral spray permits faster routes of absorption than oral tablets, which are limited by various factors, such as first pass metabolism. Azulvig will be offered in a “bag on valve” pump actuated dispenser of either 10ml or 30ml sizes. Azulvig will allow clinicians to more accurately control patient doses in order to achieve optimum control of the condition, while reducing the potential for side effects.